Please Wait.....
Report
Companion Animal Arthritis Market By Companion Type (Dog, Cat, Horse), By Arthritis Type (Osteoarthritis, Rheumatoid Arthritis), By Treatment (Exercise, Medical, Others), By Distribution Channel (Online Store, Pet Supply Store, Veterinary Hospitals and Clinics, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031
Market Report I 2023-01-01 I 298 Pages I Allied Market Research
The spread of arthritis is very common and more rapid among the companion animal population. This is the most common type of degenerative joint disease, generally known as osteoarthritis. Joints offer elastic connections and protective cushioning between bones.
Osteoarthritis causes bone growth inside joints, as well as fluid accumulation and cartilage loss. This can cause discomfort, joint deterioration, and reduced mobility over time for companion animals. A large number of medications are being introduced to the market to treat. These factors are anticipated to drive the companion animal arthritis market growth in the upcoming years. The rise in the prevalence of arthritis among pets such as dogs and cats which cause inflammation of joints is estimated to drive the companion animal arthritis market size.
The veterinary nonsteroidal anti-inflammatory drugs (NSAIDs) used for the treatment of arthritis in companion animals have a negative impact on the health of companion animals. For instance, in dogs and cats, veterinary NSAIDs can cause diarrhea, vomiting, and ulcers in the stomach and intestine. These factors are anticipated to hamper the companion animal arthritis market share during the forecast period.
The ongoing research activities for the development of therapeutic treatment for arthritis condition among animal is estimated to generate excellent growth opportunities in the market. For instance, research on companion dogs with naturally occurring illnesses inevitably provides information on how to reduce pain in companion pet dogs. Such knowledge, when paired with the safety data obtained by canine work, can serve as the foundation for a veterinary therapeutic development program. All these factors are projected to create several growth opportunities in the market.
The COVID-19 pandemic negatively impacted the companion animal arthritis market. The COVID-19 pandemic resulted in the establishment of strict lockdown and quarantine laws throughout the globe, which further restricted non-essential veterinary visits. Furthermore, the delay in medical operations has a significant impact on animal arthritis treatment. However, the introduction of the COVID-19 pandemic has increased pet adoption and foster applications, which is expected to help market expansion during the forecast period.
The key players profiled in this report include Zoetis, Virbac, Elanco, Boehringer Ingelheim International GmbH, Ceva, Dechra Pharmaceuticals PLC., Vetoquinol, NexGen Pharmaceuticals, and Norbrook.
Key Benefits For Stakeholders
-This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the companion animal arthritis market analysis from 2021 to 2031 to identify the prevailing companion animal arthritis market opportunities.
-The market research is offered along with information related to key drivers, restraints, and opportunities.
-Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
-In-depth analysis of the companion animal arthritis market segmentation assists to determine the prevailing market opportunities.
-Major countries in each region are mapped according to their revenue contribution to the global market.
-Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
-The report includes the analysis of the regional as well as global companion animal arthritis market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Companion Type
- Dog
- Cat
- Horse
By Arthritis Type
- Osteoarthritis
- Rheumatoid Arthritis
By Treatment
- Exercise
- Medical
- Others
By Distribution Channel
- Online Store
- Pet Supply Store
- Veterinary Hospitals and Clinics
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Spain
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- United Arab Emirates
- South Africa
- Rest of LAMEA
- Key Market Players
- Covetrus, Inc.
- Zoetis
- Elanco
- Virbac
- Dechra Pharmaceuticals plc
- Vetoquinol Animal Health Pvt Ltd
- Phibro Animal Health Corp
- Boehringer Ingelheim GmbH
- Bayer AG
- Ceva Sante Animale
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter's five forces analysis
3.4.Market dynamics
3.4.1.Drivers
3.4.2.Restraints
3.4.3.Opportunities
3.5.COVID-19 Impact Analysis on the market
3.6.Value Chain Analysis
3.7.Key Regulation Analysis
3.8.Patent Landscape
3.9.Regulatory Guidelines
3.10.Market Share Analysis
CHAPTER 4: COMPANION ANIMAL ARTHRITIS MARKET, BY COMPANION TYPE
4.1 Overview
4.1.1 Market size and forecast
4.2. Dog
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market share analysis by country
4.3. Cat
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market share analysis by country
4.4. Horse
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market share analysis by country
CHAPTER 5: COMPANION ANIMAL ARTHRITIS MARKET, BY ARTHRITIS TYPE
5.1 Overview
5.1.1 Market size and forecast
5.2. Osteoarthritis
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market share analysis by country
5.3. Rheumatoid Arthritis
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market share analysis by country
CHAPTER 6: COMPANION ANIMAL ARTHRITIS MARKET, BY TREATMENT
6.1 Overview
6.1.1 Market size and forecast
6.2. Exercise
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market share analysis by country
6.3. Medical
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market share analysis by country
6.4. Others
6.4.1 Key market trends, growth factors and opportunities
6.4.2 Market size and forecast, by region
6.4.3 Market share analysis by country
CHAPTER 7: COMPANION ANIMAL ARTHRITIS MARKET, BY DISTRIBUTION CHANNEL
7.1 Overview
7.1.1 Market size and forecast
7.2. Online Store
7.2.1 Key market trends, growth factors and opportunities
7.2.2 Market size and forecast, by region
7.2.3 Market share analysis by country
7.3. Pet Supply Store
7.3.1 Key market trends, growth factors and opportunities
7.3.2 Market size and forecast, by region
7.3.3 Market share analysis by country
7.4. Veterinary Hospitals and Clinics
7.4.1 Key market trends, growth factors and opportunities
7.4.2 Market size and forecast, by region
7.4.3 Market share analysis by country
7.5. Others
7.5.1 Key market trends, growth factors and opportunities
7.5.2 Market size and forecast, by region
7.5.3 Market share analysis by country
CHAPTER 8: COMPANION ANIMAL ARTHRITIS MARKET, BY REGION
8.1 Overview
8.1.1 Market size and forecast
8.2 North America
8.2.1 Key trends and opportunities
8.2.2 North America Market size and forecast, by Companion Type
8.2.3 North America Market size and forecast, by Arthritis Type
8.2.4 North America Market size and forecast, by Treatment
8.2.5 North America Market size and forecast, by Distribution Channel
8.2.6 North America Market size and forecast, by country
8.2.6.1 U.S.
8.2.6.1.1 Key market trends, growth factors and opportunities
8.2.6.1.2 Market size and forecast, by Companion Type
8.2.6.1.3 Market size and forecast, by Arthritis Type
8.2.6.1.4 Market size and forecast, by Treatment
8.2.6.1.5 Market size and forecast, by Distribution Channel
8.2.6.2 Canada
8.2.6.2.1 Key market trends, growth factors and opportunities
8.2.6.2.2 Market size and forecast, by Companion Type
8.2.6.2.3 Market size and forecast, by Arthritis Type
8.2.6.2.4 Market size and forecast, by Treatment
8.2.6.2.5 Market size and forecast, by Distribution Channel
8.2.6.3 Mexico
8.2.6.3.1 Key market trends, growth factors and opportunities
8.2.6.3.2 Market size and forecast, by Companion Type
8.2.6.3.3 Market size and forecast, by Arthritis Type
8.2.6.3.4 Market size and forecast, by Treatment
8.2.6.3.5 Market size and forecast, by Distribution Channel
8.3 Europe
8.3.1 Key trends and opportunities
8.3.2 Europe Market size and forecast, by Companion Type
8.3.3 Europe Market size and forecast, by Arthritis Type
8.3.4 Europe Market size and forecast, by Treatment
8.3.5 Europe Market size and forecast, by Distribution Channel
8.3.6 Europe Market size and forecast, by country
8.3.6.1 Germany
8.3.6.1.1 Key market trends, growth factors and opportunities
8.3.6.1.2 Market size and forecast, by Companion Type
8.3.6.1.3 Market size and forecast, by Arthritis Type
8.3.6.1.4 Market size and forecast, by Treatment
8.3.6.1.5 Market size and forecast, by Distribution Channel
8.3.6.2 UK
8.3.6.2.1 Key market trends, growth factors and opportunities
8.3.6.2.2 Market size and forecast, by Companion Type
8.3.6.2.3 Market size and forecast, by Arthritis Type
8.3.6.2.4 Market size and forecast, by Treatment
8.3.6.2.5 Market size and forecast, by Distribution Channel
8.3.6.3 France
8.3.6.3.1 Key market trends, growth factors and opportunities
8.3.6.3.2 Market size and forecast, by Companion Type
8.3.6.3.3 Market size and forecast, by Arthritis Type
8.3.6.3.4 Market size and forecast, by Treatment
8.3.6.3.5 Market size and forecast, by Distribution Channel
8.3.6.4 Spain
8.3.6.4.1 Key market trends, growth factors and opportunities
8.3.6.4.2 Market size and forecast, by Companion Type
8.3.6.4.3 Market size and forecast, by Arthritis Type
8.3.6.4.4 Market size and forecast, by Treatment
8.3.6.4.5 Market size and forecast, by Distribution Channel
8.3.6.5 Italy
8.3.6.5.1 Key market trends, growth factors and opportunities
8.3.6.5.2 Market size and forecast, by Companion Type
8.3.6.5.3 Market size and forecast, by Arthritis Type
8.3.6.5.4 Market size and forecast, by Treatment
8.3.6.5.5 Market size and forecast, by Distribution Channel
8.3.6.6 Rest of Europe
8.3.6.6.1 Key market trends, growth factors and opportunities
8.3.6.6.2 Market size and forecast, by Companion Type
8.3.6.6.3 Market size and forecast, by Arthritis Type
8.3.6.6.4 Market size and forecast, by Treatment
8.3.6.6.5 Market size and forecast, by Distribution Channel
8.4 Asia-Pacific
8.4.1 Key trends and opportunities
8.4.2 Asia-Pacific Market size and forecast, by Companion Type
8.4.3 Asia-Pacific Market size and forecast, by Arthritis Type
8.4.4 Asia-Pacific Market size and forecast, by Treatment
8.4.5 Asia-Pacific Market size and forecast, by Distribution Channel
8.4.6 Asia-Pacific Market size and forecast, by country
8.4.6.1 China
8.4.6.1.1 Key market trends, growth factors and opportunities
8.4.6.1.2 Market size and forecast, by Companion Type
8.4.6.1.3 Market size and forecast, by Arthritis Type
8.4.6.1.4 Market size and forecast, by Treatment
8.4.6.1.5 Market size and forecast, by Distribution Channel
8.4.6.2 Japan
8.4.6.2.1 Key market trends, growth factors and opportunities
8.4.6.2.2 Market size and forecast, by Companion Type
8.4.6.2.3 Market size and forecast, by Arthritis Type
8.4.6.2.4 Market size and forecast, by Treatment
8.4.6.2.5 Market size and forecast, by Distribution Channel
8.4.6.3 India
8.4.6.3.1 Key market trends, growth factors and opportunities
8.4.6.3.2 Market size and forecast, by Companion Type
8.4.6.3.3 Market size and forecast, by Arthritis Type
8.4.6.3.4 Market size and forecast, by Treatment
8.4.6.3.5 Market size and forecast, by Distribution Channel
8.4.6.4 South Korea
8.4.6.4.1 Key market trends, growth factors and opportunities
8.4.6.4.2 Market size and forecast, by Companion Type
8.4.6.4.3 Market size and forecast, by Arthritis Type
8.4.6.4.4 Market size and forecast, by Treatment
8.4.6.4.5 Market size and forecast, by Distribution Channel
8.4.6.5 Australia
8.4.6.5.1 Key market trends, growth factors and opportunities
8.4.6.5.2 Market size and forecast, by Companion Type
8.4.6.5.3 Market size and forecast, by Arthritis Type
8.4.6.5.4 Market size and forecast, by Treatment
8.4.6.5.5 Market size and forecast, by Distribution Channel
8.4.6.6 Rest of Asia-Pacific
8.4.6.6.1 Key market trends, growth factors and opportunities
8.4.6.6.2 Market size and forecast, by Companion Type
8.4.6.6.3 Market size and forecast, by Arthritis Type
8.4.6.6.4 Market size and forecast, by Treatment
8.4.6.6.5 Market size and forecast, by Distribution Channel
8.5 LAMEA
8.5.1 Key trends and opportunities
8.5.2 LAMEA Market size and forecast, by Companion Type
8.5.3 LAMEA Market size and forecast, by Arthritis Type
8.5.4 LAMEA Market size and forecast, by Treatment
8.5.5 LAMEA Market size and forecast, by Distribution Channel
8.5.6 LAMEA Market size and forecast, by country
8.5.6.1 Brazil
8.5.6.1.1 Key market trends, growth factors and opportunities
8.5.6.1.2 Market size and forecast, by Companion Type
8.5.6.1.3 Market size and forecast, by Arthritis Type
8.5.6.1.4 Market size and forecast, by Treatment
8.5.6.1.5 Market size and forecast, by Distribution Channel
8.5.6.2 Saudi Arabia
8.5.6.2.1 Key market trends, growth factors and opportunities
8.5.6.2.2 Market size and forecast, by Companion Type
8.5.6.2.3 Market size and forecast, by Arthritis Type
8.5.6.2.4 Market size and forecast, by Treatment
8.5.6.2.5 Market size and forecast, by Distribution Channel
8.5.6.3 United Arab Emirates
8.5.6.3.1 Key market trends, growth factors and opportunities
8.5.6.3.2 Market size and forecast, by Companion Type
8.5.6.3.3 Market size and forecast, by Arthritis Type
8.5.6.3.4 Market size and forecast, by Treatment
8.5.6.3.5 Market size and forecast, by Distribution Channel
8.5.6.4 South Africa
8.5.6.4.1 Key market trends, growth factors and opportunities
8.5.6.4.2 Market size and forecast, by Companion Type
8.5.6.4.3 Market size and forecast, by Arthritis Type
8.5.6.4.4 Market size and forecast, by Treatment
8.5.6.4.5 Market size and forecast, by Distribution Channel
8.5.6.5 Rest of LAMEA
8.5.6.5.1 Key market trends, growth factors and opportunities
8.5.6.5.2 Market size and forecast, by Companion Type
8.5.6.5.3 Market size and forecast, by Arthritis Type
8.5.6.5.4 Market size and forecast, by Treatment
8.5.6.5.5 Market size and forecast, by Distribution Channel
CHAPTER 9: COMPETITIVE LANDSCAPE
9.1. Introduction
9.2. Top winning strategies
9.3. Product Mapping of Top 10 Player
9.4. Competitive Dashboard
9.5. Competitive Heatmap
9.6. Top player positioning, 2021
CHAPTER 10: COMPANY PROFILES
10.1 Covetrus, Inc.
10.1.1 Company overview
10.1.2 Key Executives
10.1.3 Company snapshot
10.1.4 Operating business segments
10.1.5 Product portfolio
10.1.6 Business performance
10.1.7 Key strategic moves and developments
10.2 Zoetis
10.2.1 Company overview
10.2.2 Key Executives
10.2.3 Company snapshot
10.2.4 Operating business segments
10.2.5 Product portfolio
10.2.6 Business performance
10.2.7 Key strategic moves and developments
10.3 Elanco
10.3.1 Company overview
10.3.2 Key Executives
10.3.3 Company snapshot
10.3.4 Operating business segments
10.3.5 Product portfolio
10.3.6 Business performance
10.3.7 Key strategic moves and developments
10.4 Virbac
10.4.1 Company overview
10.4.2 Key Executives
10.4.3 Company snapshot
10.4.4 Operating business segments
10.4.5 Product portfolio
10.4.6 Business performance
10.4.7 Key strategic moves and developments
10.5 Dechra Pharmaceuticals plc
10.5.1 Company overview
10.5.2 Key Executives
10.5.3 Company snapshot
10.5.4 Operating business segments
10.5.5 Product portfolio
10.5.6 Business performance
10.5.7 Key strategic moves and developments
10.6 Vetoquinol Animal Health Pvt Ltd
10.6.1 Company overview
10.6.2 Key Executives
10.6.3 Company snapshot
10.6.4 Operating business segments
10.6.5 Product portfolio
10.6.6 Business performance
10.6.7 Key strategic moves and developments
10.7 Phibro Animal Health Corp
10.7.1 Company overview
10.7.2 Key Executives
10.7.3 Company snapshot
10.7.4 Operating business segments
10.7.5 Product portfolio
10.7.6 Business performance
10.7.7 Key strategic moves and developments
10.8 Boehringer Ingelheim GmbH
10.8.1 Company overview
10.8.2 Key Executives
10.8.3 Company snapshot
10.8.4 Operating business segments
10.8.5 Product portfolio
10.8.6 Business performance
10.8.7 Key strategic moves and developments
10.9 Bayer AG
10.9.1 Company overview
10.9.2 Key Executives
10.9.3 Company snapshot
10.9.4 Operating business segments
10.9.5 Product portfolio
10.9.6 Business performance
10.9.7 Key strategic moves and developments
10.10 Ceva Sante Animale
10.10.1 Company overview
10.10.2 Key Executives
10.10.3 Company snapshot
10.10.4 Operating business segments
10.10.5 Product portfolio
10.10.6 Business performance
10.10.7 Key strategic moves and developments
LIST OF TABLES
TABLE 1. GLOBAL COMPANION ANIMAL ARTHRITIS MARKET, BY COMPANION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 2. COMPANION ANIMAL ARTHRITIS MARKET FOR DOG, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 3. COMPANION ANIMAL ARTHRITIS MARKET FOR CAT, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 4. COMPANION ANIMAL ARTHRITIS MARKET FOR HORSE, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 5. GLOBAL COMPANION ANIMAL ARTHRITIS MARKET, BY ARTHRITIS TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 6. COMPANION ANIMAL ARTHRITIS MARKET FOR OSTEOARTHRITIS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 7. COMPANION ANIMAL ARTHRITIS MARKET FOR RHEUMATOID ARTHRITIS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 8. GLOBAL COMPANION ANIMAL ARTHRITIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 9. COMPANION ANIMAL ARTHRITIS MARKET FOR EXERCISE, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 10. COMPANION ANIMAL ARTHRITIS MARKET FOR MEDICAL, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 11. COMPANION ANIMAL ARTHRITIS MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 12. GLOBAL COMPANION ANIMAL ARTHRITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 13. COMPANION ANIMAL ARTHRITIS MARKET FOR ONLINE STORE, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 14. COMPANION ANIMAL ARTHRITIS MARKET FOR PET SUPPLY STORE, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 15. COMPANION ANIMAL ARTHRITIS MARKET FOR VETERINARY HOSPITALS AND CLINICS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 16. COMPANION ANIMAL ARTHRITIS MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 17. COMPANION ANIMAL ARTHRITIS MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 18. NORTH AMERICA COMPANION ANIMAL ARTHRITIS MARKET, BY COMPANION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 19. NORTH AMERICA COMPANION ANIMAL ARTHRITIS MARKET, BY ARTHRITIS TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 20. NORTH AMERICA COMPANION ANIMAL ARTHRITIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 21. NORTH AMERICA COMPANION ANIMAL ARTHRITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 22. NORTH AMERICA COMPANION ANIMAL ARTHRITIS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 23. U.S. COMPANION ANIMAL ARTHRITIS MARKET, BY COMPANION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 24. U.S. COMPANION ANIMAL ARTHRITIS MARKET, BY ARTHRITIS TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 25. U.S. COMPANION ANIMAL ARTHRITIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 26. U.S. COMPANION ANIMAL ARTHRITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 27. CANADA COMPANION ANIMAL ARTHRITIS MARKET, BY COMPANION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 28. CANADA COMPANION ANIMAL ARTHRITIS MARKET, BY ARTHRITIS TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 29. CANADA COMPANION ANIMAL ARTHRITIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 30. CANADA COMPANION ANIMAL ARTHRITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 31. MEXICO COMPANION ANIMAL ARTHRITIS MARKET, BY COMPANION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 32. MEXICO COMPANION ANIMAL ARTHRITIS MARKET, BY ARTHRITIS TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 33. MEXICO COMPANION ANIMAL ARTHRITIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 34. MEXICO COMPANION ANIMAL ARTHRITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 35. EUROPE COMPANION ANIMAL ARTHRITIS MARKET, BY COMPANION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 36. EUROPE COMPANION ANIMAL ARTHRITIS MARKET, BY ARTHRITIS TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 37. EUROPE COMPANION ANIMAL ARTHRITIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 38. EUROPE COMPANION ANIMAL ARTHRITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 39. EUROPE COMPANION ANIMAL ARTHRITIS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 40. GERMANY COMPANION ANIMAL ARTHRITIS MARKET, BY COMPANION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 41. GERMANY COMPANION ANIMAL ARTHRITIS MARKET, BY ARTHRITIS TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 42. GERMANY COMPANION ANIMAL ARTHRITIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 43. GERMANY COMPANION ANIMAL ARTHRITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 44. UK COMPANION ANIMAL ARTHRITIS MARKET, BY COMPANION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 45. UK COMPANION ANIMAL ARTHRITIS MARKET, BY ARTHRITIS TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 46. UK COMPANION ANIMAL ARTHRITIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 47. UK COMPANION ANIMAL ARTHRITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 48. FRANCE COMPANION ANIMAL ARTHRITIS MARKET, BY COMPANION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 49. FRANCE COMPANION ANIMAL ARTHRITIS MARKET, BY ARTHRITIS TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 50. FRANCE COMPANION ANIMAL ARTHRITIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 51. FRANCE COMPANION ANIMAL ARTHRITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 52. SPAIN COMPANION ANIMAL ARTHRITIS MARKET, BY COMPANION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 53. SPAIN COMPANION ANIMAL ARTHRITIS MARKET, BY ARTHRITIS TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 54. SPAIN COMPANION ANIMAL ARTHRITIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 55. SPAIN COMPANION ANIMAL ARTHRITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 56. ITALY COMPANION ANIMAL ARTHRITIS MARKET, BY COMPANION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 57. ITALY COMPANION ANIMAL ARTHRITIS MARKET, BY ARTHRITIS TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 58. ITALY COMPANION ANIMAL ARTHRITIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 59. ITALY COMPANION ANIMAL ARTHRITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 60. REST OF EUROPE COMPANION ANIMAL ARTHRITIS MARKET, BY COMPANION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 61. REST OF EUROPE COMPANION ANIMAL ARTHRITIS MARKET, BY ARTHRITIS TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 62. REST OF EUROPE COMPANION ANIMAL ARTHRITIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 63. REST OF EUROPE COMPANION ANIMAL ARTHRITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 64. ASIA-PACIFIC COMPANION ANIMAL ARTHRITIS MARKET, BY COMPANION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 65. ASIA-PACIFIC COMPANION ANIMAL ARTHRITIS MARKET, BY ARTHRITIS TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 66. ASIA-PACIFIC COMPANION ANIMAL ARTHRITIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 67. ASIA-PACIFIC COMPANION ANIMAL ARTHRITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 68. ASIA-PACIFIC COMPANION ANIMAL ARTHRITIS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 69. CHINA COMPANION ANIMAL ARTHRITIS MARKET, BY COMPANION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 70. CHINA COMPANION ANIMAL ARTHRITIS MARKET, BY ARTHRITIS TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 71. CHINA COMPANION ANIMAL ARTHRITIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 72. CHINA COMPANION ANIMAL ARTHRITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 73. JAPAN COMPANION ANIMAL ARTHRITIS MARKET, BY COMPANION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 74. JAPAN COMPANION ANIMAL ARTHRITIS MARKET, BY ARTHRITIS TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 75. JAPAN COMPANION ANIMAL ARTHRITIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 76. JAPAN COMPANION ANIMAL ARTHRITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 77. INDIA COMPANION ANIMAL ARTHRITIS MARKET, BY COMPANION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 78. INDIA COMPANION ANIMAL ARTHRITIS MARKET, BY ARTHRITIS TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 79. INDIA COMPANION ANIMAL ARTHRITIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 80. INDIA COMPANION ANIMAL ARTHRITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 81. SOUTH KOREA COMPANION ANIMAL ARTHRITIS MARKET, BY COMPANION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 82. SOUTH KOREA COMPANION ANIMAL ARTHRITIS MARKET, BY ARTHRITIS TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 83. SOUTH KOREA COMPANION ANIMAL ARTHRITIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 84. SOUTH KOREA COMPANION ANIMAL ARTHRITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 85. AUSTRALIA COMPANION ANIMAL ARTHRITIS MARKET, BY COMPANION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 86. AUSTRALIA COMPANION ANIMAL ARTHRITIS MARKET, BY ARTHRITIS TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 87. AUSTRALIA COMPANION ANIMAL ARTHRITIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 88. AUSTRALIA COMPANION ANIMAL ARTHRITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 89. REST OF ASIA-PACIFIC COMPANION ANIMAL ARTHRITIS MARKET, BY COMPANION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 90. REST OF ASIA-PACIFIC COMPANION ANIMAL ARTHRITIS MARKET, BY ARTHRITIS TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 91. REST OF ASIA-PACIFIC COMPANION ANIMAL ARTHRITIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 92. REST OF ASIA-PACIFIC COMPANION ANIMAL ARTHRITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 93. LAMEA COMPANION ANIMAL ARTHRITIS MARKET, BY COMPANION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 94. LAMEA COMPANION ANIMAL ARTHRITIS MARKET, BY ARTHRITIS TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 95. LAMEA COMPANION ANIMAL ARTHRITIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 96. LAMEA COMPANION ANIMAL ARTHRITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 97. LAMEA COMPANION ANIMAL ARTHRITIS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 98. BRAZIL COMPANION ANIMAL ARTHRITIS MARKET, BY COMPANION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 99. BRAZIL COMPANION ANIMAL ARTHRITIS MARKET, BY ARTHRITIS TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 100. BRAZIL COMPANION ANIMAL ARTHRITIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 101. BRAZIL COMPANION ANIMAL ARTHRITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 102. SAUDI ARABIA COMPANION ANIMAL ARTHRITIS MARKET, BY COMPANION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 103. SAUDI ARABIA COMPANION ANIMAL ARTHRITIS MARKET, BY ARTHRITIS TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 104. SAUDI ARABIA COMPANION ANIMAL ARTHRITIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 105. SAUDI ARABIA COMPANION ANIMAL ARTHRITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 106. UNITED ARAB EMIRATES COMPANION ANIMAL ARTHRITIS MARKET, BY COMPANION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 107. UNITED ARAB EMIRATES COMPANION ANIMAL ARTHRITIS MARKET, BY ARTHRITIS TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 108. UNITED ARAB EMIRATES COMPANION ANIMAL ARTHRITIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 109. UNITED ARAB EMIRATES COMPANION ANIMAL ARTHRITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 110. SOUTH AFRICA COMPANION ANIMAL ARTHRITIS MARKET, BY COMPANION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 111. SOUTH AFRICA COMPANION ANIMAL ARTHRITIS MARKET, BY ARTHRITIS TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 112. SOUTH AFRICA COMPANION ANIMAL ARTHRITIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 113. SOUTH AFRICA COMPANION ANIMAL ARTHRITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 114. REST OF LAMEA COMPANION ANIMAL ARTHRITIS MARKET, BY COMPANION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 115. REST OF LAMEA COMPANION ANIMAL ARTHRITIS MARKET, BY ARTHRITIS TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 116. REST OF LAMEA COMPANION ANIMAL ARTHRITIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 117. REST OF LAMEA COMPANION ANIMAL ARTHRITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 118. COVETRUS, INC.: KEY EXECUTIVES
TABLE 119. COVETRUS, INC.: COMPANY SNAPSHOT
TABLE 120. COVETRUS, INC.: OPERATING SEGMENTS
TABLE 121. COVETRUS, INC.: PRODUCT PORTFOLIO
TABLE 122. COVETRUS, INC.: NET SALES
TABLE 123. COVETRUS, INC.: KEY STRATERGIES
TABLE 124. ZOETIS: KEY EXECUTIVES
TABLE 125. ZOETIS: COMPANY SNAPSHOT
TABLE 126. ZOETIS: OPERATING SEGMENTS
TABLE 127. ZOETIS: PRODUCT PORTFOLIO
TABLE 128. ZOETIS: NET SALES
TABLE 129. ZOETIS: KEY STRATERGIES
TABLE 130. ELANCO: KEY EXECUTIVES
TABLE 131. ELANCO: COMPANY SNAPSHOT
TABLE 132. ELANCO: OPERATING SEGMENTS
TABLE 133. ELANCO: PRODUCT PORTFOLIO
TABLE 134. ELANCO: NET SALES
TABLE 135. ELANCO: KEY STRATERGIES
TABLE 136. VIRBAC: KEY EXECUTIVES
TABLE 137. VIRBAC: COMPANY SNAPSHOT
TABLE 138. VIRBAC: OPERATING SEGMENTS
TABLE 139. VIRBAC: PRODUCT PORTFOLIO
TABLE 140. VIRBAC: NET SALES
TABLE 141. VIRBAC: KEY STRATERGIES
TABLE 142. DECHRA PHARMACEUTICALS PLC: KEY EXECUTIVES
TABLE 143. DECHRA PHARMACEUTICALS PLC: COMPANY SNAPSHOT
TABLE 144. DECHRA PHARMACEUTICALS PLC: OPERATING SEGMENTS
TABLE 145. DECHRA PHARMACEUTICALS PLC: PRODUCT PORTFOLIO
TABLE 146. DECHRA PHARMACEUTICALS PLC: NET SALES
TABLE 147. DECHRA PHARMACEUTICALS PLC: KEY STRATERGIES
TABLE 148. VETOQUINOL ANIMAL HEALTH PVT LTD: KEY EXECUTIVES
TABLE 149. VETOQUINOL ANIMAL HEALTH PVT LTD: COMPANY SNAPSHOT
TABLE 150. VETOQUINOL ANIMAL HEALTH PVT LTD: OPERATING SEGMENTS
TABLE 151. VETOQUINOL ANIMAL HEALTH PVT LTD: PRODUCT PORTFOLIO
TABLE 152. VETOQUINOL ANIMAL HEALTH PVT LTD: NET SALES
TABLE 153. VETOQUINOL ANIMAL HEALTH PVT LTD: KEY STRATERGIES
TABLE 154. PHIBRO ANIMAL HEALTH CORP: KEY EXECUTIVES
TABLE 155. PHIBRO ANIMAL HEALTH CORP: COMPANY SNAPSHOT
TABLE 156. PHIBRO ANIMAL HEALTH CORP: OPERATING SEGMENTS
TABLE 157. PHIBRO ANIMAL HEALTH CORP: PRODUCT PORTFOLIO
TABLE 158. PHIBRO ANIMAL HEALTH CORP: NET SALES
TABLE 159. PHIBRO ANIMAL HEALTH CORP: KEY STRATERGIES
TABLE 160. BOEHRINGER INGELHEIM GMBH: KEY EXECUTIVES
TABLE 161. BOEHRINGER INGELHEIM GMBH: COMPANY SNAPSHOT
TABLE 162. BOEHRINGER INGELHEIM GMBH: OPERATING SEGMENTS
TABLE 163. BOEHRINGER INGELHEIM GMBH: PRODUCT PORTFOLIO
TABLE 164. BOEHRINGER INGELHEIM GMBH: NET SALES
TABLE 165. BOEHRINGER INGELHEIM GMBH: KEY STRATERGIES
TABLE 166. BAYER AG: KEY EXECUTIVES
TABLE 167. BAYER AG: COMPANY SNAPSHOT
TABLE 168. BAYER AG: OPERATING SEGMENTS
TABLE 169. BAYER AG: PRODUCT PORTFOLIO
TABLE 170. BAYER AG: NET SALES
TABLE 171. BAYER AG: KEY STRATERGIES
TABLE 172. CEVA SANTE ANIMALE: KEY EXECUTIVES
TABLE 173. CEVA SANTE ANIMALE: COMPANY SNAPSHOT
TABLE 174. CEVA SANTE ANIMALE: OPERATING SEGMENTS
TABLE 175. CEVA SANTE ANIMALE: PRODUCT PORTFOLIO
TABLE 176. CEVA SANTE ANIMALE: NET SALES
TABLE 177. CEVA SANTE ANIMALE: KEY STRATERGIES
LIST OF FIGURES
FIGURE 1. SEGMENTATION OF COMPANION ANIMAL ARTHRITIS MARKET,2021-2031
FIGURE 2. COMPANION ANIMAL ARTHRITIS MARKET,2021-2031
FIGURE 3. TOP INVESTMENT POCKETS, BY REGION
FIGURE 4. PORTER FIVE-1
FIGURE 5. PORTER FIVE-2
FIGURE 6. PORTER FIVE-3
FIGURE 7. PORTER FIVE-4
FIGURE 8. PORTER FIVE-5
FIGURE 9. COMPANION ANIMAL ARTHRITIS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 10. VALUE CHAIN ANALYSIS
FIGURE 11. KEY REGULATION ANALYSIS
FIGURE 12. PATENT ANALYSIS BY COMPANY
FIGURE 13. PATENT ANALYSIS BY COUNTRY
FIGURE 14. REGULATORY GUIDELINES
FIGURE 15. MARKET SHARE ANALYSIS
FIGURE 16. COMPANION ANIMAL ARTHRITIS MARKET,BY COMPANION TYPE,2021(%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF DOG COMPANION ANIMAL ARTHRITIS MARKET, 2021 AND 2031(%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF CAT COMPANION ANIMAL ARTHRITIS MARKET, 2021 AND 2031(%)
FIGURE 19. COMPARATIVE SHARE ANALYSIS OF HORSE COMPANION ANIMAL ARTHRITIS MARKET, 2021 AND 2031(%)
FIGURE 20. COMPANION ANIMAL ARTHRITIS MARKET,BY ARTHRITIS TYPE,2021(%)
FIGURE 21. COMPARATIVE SHARE ANALYSIS OF OSTEOARTHRITIS COMPANION ANIMAL ARTHRITIS MARKET, 2021 AND 2031(%)
FIGURE 22. COMPARATIVE SHARE ANALYSIS OF RHEUMATOID ARTHRITIS COMPANION ANIMAL ARTHRITIS MARKET, 2021 AND 2031(%)
FIGURE 23. COMPANION ANIMAL ARTHRITIS MARKET,BY TREATMENT,2021(%)
FIGURE 24. COMPARATIVE SHARE ANALYSIS OF EXERCISE COMPANION ANIMAL ARTHRITIS MARKET, 2021 AND 2031(%)
FIGURE 25. COMPARATIVE SHARE ANALYSIS OF MEDICAL COMPANION ANIMAL ARTHRITIS MARKET, 2021 AND 2031(%)
FIGURE 26. COMPARATIVE SHARE ANALYSIS OF OTHERS COMPANION ANIMAL ARTHRITIS MARKET, 2021 AND 2031(%)
FIGURE 27. COMPANION ANIMAL ARTHRITIS MARKET,BY DISTRIBUTION CHANNEL,2021(%)
FIGURE 28. COMPARATIVE SHARE ANALYSIS OF ONLINE STORE COMPANION ANIMAL ARTHRITIS MARKET, 2021 AND 2031(%)
FIGURE 29. COMPARATIVE SHARE ANALYSIS OF PET SUPPLY STORE COMPANION ANIMAL ARTHRITIS MARKET, 2021 AND 2031(%)
FIGURE 30. COMPARATIVE SHARE ANALYSIS OF VETERINARY HOSPITALS AND CLINICS COMPANION ANIMAL ARTHRITIS MARKET, 2021 AND 2031(%)
FIGURE 31. COMPARATIVE SHARE ANALYSIS OF OTHERS COMPANION ANIMAL ARTHRITIS MARKET, 2021 AND 2031(%)
FIGURE 32. COMPANION ANIMAL ARTHRITIS MARKET BY REGION,2021
FIGURE 33. U.S. COMPANION ANIMAL ARTHRITIS MARKET,2021-2031($MILLION)
FIGURE 34. CANADA COMPANION ANIMAL ARTHRITIS MARKET,2021-2031($MILLION)
FIGURE 35. MEXICO COMPANION ANIMAL ARTHRITIS MARKET,2021-2031($MILLION)
FIGURE 36. GERMANY COMPANION ANIMAL ARTHRITIS MARKET,2021-2031($MILLION)
FIGURE 37. UK COMPANION ANIMAL ARTHRITIS MARKET,2021-2031($MILLION)
FIGURE 38. FRANCE COMPANION ANIMAL ARTHRITIS MARKET,2021-2031($MILLION)
FIGURE 39. SPAIN COMPANION ANIMAL ARTHRITIS MARKET,2021-2031($MILLION)
FIGURE 40. ITALY COMPANION ANIMAL ARTHRITIS MARKET,2021-2031($MILLION)
FIGURE 41. REST OF EUROPE COMPANION ANIMAL ARTHRITIS MARKET,2021-2031($MILLION)
FIGURE 42. CHINA COMPANION ANIMAL ARTHRITIS MARKET,2021-2031($MILLION)
FIGURE 43. JAPAN COMPANION ANIMAL ARTHRITIS MARKET,2021-2031($MILLION)
FIGURE 44. INDIA COMPANION ANIMAL ARTHRITIS MARKET,2021-2031($MILLION)
FIGURE 45. SOUTH KOREA COMPANION ANIMAL ARTHRITIS MARKET,2021-2031($MILLION)
FIGURE 46. AUSTRALIA COMPANION ANIMAL ARTHRITIS MARKET,2021-2031($MILLION)
FIGURE 47. REST OF ASIA-PACIFIC COMPANION ANIMAL ARTHRITIS MARKET,2021-2031($MILLION)
FIGURE 48. BRAZIL COMPANION ANIMAL ARTHRITIS MARKET,2021-2031($MILLION)
FIGURE 49. SAUDI ARABIA COMPANION ANIMAL ARTHRITIS MARKET,2021-2031($MILLION)
FIGURE 50. UNITED ARAB EMIRATES COMPANION ANIMAL ARTHRITIS MARKET,2021-2031($MILLION)
FIGURE 51. SOUTH AFRICA COMPANION ANIMAL ARTHRITIS MARKET,2021-2031($MILLION)
FIGURE 52. REST OF LAMEA COMPANION ANIMAL ARTHRITIS MARKET,2021-2031($MILLION)
FIGURE 53. TOP WINNING STRATEGIES, BY YEAR
FIGURE 54. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 55. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 56. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 57. COMPETITIVE DASHBOARD
FIGURE 58. COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
FIGURE 59. TOP PLAYER POSITIONING, 2021
FIGURE 60. COVETRUS, INC..: NET SALES ($MILLION)
FIGURE 61. ZOETIS.: NET SALES ($MILLION)
FIGURE 62. ELANCO.: NET SALES ($MILLION)
FIGURE 63. VIRBAC.: NET SALES ($MILLION)
FIGURE 64. DECHRA PHARMACEUTICALS PLC.: NET SALES ($MILLION)
FIGURE 65. VETOQUINOL ANIMAL HEALTH PVT LTD.: NET SALES ($MILLION)
FIGURE 66. PHIBRO ANIMAL HEALTH CORP.: NET SALES ($MILLION)
FIGURE 67. BOEHRINGER INGELHEIM GMBH.: NET SALES ($MILLION)
FIGURE 68. BAYER AG.: NET SALES ($MILLION)
FIGURE 69. CEVA SANTE ANIMALE.: NET SALES ($MILLION)
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security